physioneal 40 glukoza 3,86% w/v 38.6 g/1 l+ 5.38 g/1 l+ 0.184 g/1 l+ 0.051 g/1 l+ 2.1 g/1 l+ 1.68 g/1 l rastvor za peritonealnu
co.medprom d.o.o. banja luka - glukoza, kalcijumhlorid, magnezijumhlorid, natrijum bikarbonat, natrijumhlorid, natrijumlaktat - rastvor za peritonealnu dijalizu - 38.6 g/1 l+ 5.38 g/1 l+ 0.184 g/1 l+ 0.051 g/1 l+ 2.1 g/1 l+ 1.68 g/1 l - nakon mješanja rastvora iz komora a i b, 1 l rastvora za peritonealnu dijalizu sadrži: 38,6 g glukoze (u obliku glukoze monohidrata) 5,38 g natrijum hlorida 0,184 g kalcijumhlorid, dihidrata 0,051 g magnezijumhlorid heksahidrata 2,10 g natrijum bikarbonata 1,68 g natrijum laktata
yervoy
bristol-myers squibb pharma eeig - Ипилимумаб - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 i 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.
depocyte
pacira limited - kitarabin - meningalne neoplazme - antineoplastična sredstva - intratekalno liječenje limfomatoznog meningitisa. u većine bolesnika takav tretman će biti dio simptomatsko liječenja bolesti.
aspiramatic sustav
oktal pharma d.o.o., zagreb - dezinficijens za svakodnevnu dezinfekciju u stomatologiji
gigasept instru af
oktal pharma d.o.o., zagreb - dezinfekcija i čišćenje kirurških instrumenata, pribora za anesteziju i slično, tekući koncentrat od 2 l i 5 l
mikrozid maramice a 200 komada
oktal pharma d.o.o., zagreb - dezinfekcija i čišćenje medicinskih instrumenata i pribora
mikrozid otopina
oktal pharma d.o.o., zagreb - dezinfekcija prostora u zdravstvenim ustanovama raspršivanjem
mikrozid sensitive maramice a 200 komada
oktal pharma d.o.o., zagreb - dezinfekcija i čišćenje medicinskih instrumenata, radnih površina i pribora
mikrozid sensitive otopina
oktal pharma d.o.o., zagreb - dezinfekcija medicinskih proizvoda te ostalih radnih površina
octenisept gel za rane
oktal pharma d.o.o., zagreb - gel za rane koji vlaži kožu i štiti ranu od novih infekcija